Telix Pharmaceuticals (TLX) Total Current Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Total Current Liabilities for 3 consecutive years, with $231.6 million the latest figure, recorded in Q4 2025.

• Quarterly Total Current Liabilities fell 0.89% year-over-year to $231.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $231.6 million (down 0.89% YoY) and the FY2025 annual result came in at $231.6 million, up 12.94% from the prior year.
• Total Current Liabilities retreated to $231.6 million in Q4 2025 per TLX's latest filing, from $233.7 million in the prior quarter.
• Over the last five years, Total Current Liabilities for TLX reached as high as $233.7 million in Q4 2024 and fell as low as $116.6 million in Q4 2023.
• A 3-year average of $194.0 million and a median of $231.6 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities surged 100.47% — and 2025, when it declined 0.89%.
• Year by year, Total Current Liabilities stood at $116.6 million in 2023, then jumped by 100.47% to $233.7 million in 2024, then fell by 0.89% to $231.6 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $231.6 million, $233.7 million, and $116.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.